Phillip Md Et Al Frost has bought stock on 376 days since Dec 2015
Director at Cocrystal Pharma, Inc., and 10 other companies
SEC CIK 0000898860 · Filings on SEC.gov ↗
Phillip Md Et Al Frost's record
3 months after each buy, from the first price a copier could get.
67 buys since 2019 with 3 months of prices.
Companies
- COCP Cocrystal Pharma, Inc.Director
- OPK OPKO Health, Inc.CEO, Chair and 10% owner
- NNUP Nocopi Technologies, Inc.10% owner
- BCDA BioCardia, Inc.10% owner
- FLNT Fluent, Inc.10% owner
- VGR Vector Group Ltd10% owner
- ROX Castle Brands IncDirector and 10% owner
- LTS Ladenburg Thalmann Financial Services Inc.Former 10% Owner
- NIMU Non-Invasive Monitoring Systems Inc10% owner
- IDI Idi, Inc.Director and 10% owner
- CDOM Tiger X Medical, Inc.10% owner
Every filing
387 filings since Jan 2016, newest first
Opko Health, Inc.
CEO, Chair and 10% owner
Opko Health, Inc.
CEO, Chair and 10% owner
Opko Health, Inc.
CEO, Chair and 10% owner
Opko Health, Inc.
CEO, Chair and 10% owner
Opko Health, Inc.
CEO, Chair and 10% owner
Opko Health, Inc.
CEO, Chair and 10% owner
Opko Health, Inc.
CEO, Chair and 10% owner
Opko Health, Inc.
CEO, Chair and 10% owner
Opko Health, Inc.
CEO, Chair and 10% owner
Opko Health, Inc.
CEO, Chair and 10% owner
Opko Health, Inc.
CEO, Chair and 10% owner
Opko Health, Inc.
CEO, Chair and 10% owner
Opko Health, Inc.
CEO, Chair and 10% owner
Opko Health, Inc.
CEO, Chair and 10% owner
Opko Health, Inc.
CEO, Chair and 10% owner
Opko Health, Inc.
CEO, Chair and 10% owner
Opko Health, Inc.
CEO, Chair and 10% owner
Opko Health, Inc.
CEO, Chair and 10% owner
Opko Health, Inc.
CEO, Chair and 10% owner
Opko Health, Inc.
CEO, Chair and 10% owner
Opko Health, Inc.
CEO, Chair and 10% owner
Opko Health, Inc.
CEO, Chair and 10% owner
Opko Health, Inc.
CEO, Chair and 10% owner
Opko Health, Inc.
CEO, Chair and 10% owner
Opko Health, Inc.
CEO, Chair and 10% owner
Opko Health, Inc.
CEO, Chair and 10% owner
Opko Health, Inc.
CEO, Chair and 10% owner
Opko Health, Inc.
CEO, Chair and 10% owner
Opko Health, Inc.
CEO, Chair and 10% owner
Opko Health, Inc.
CEO, Chair and 10% owner
Opko Health, Inc.
CEO, Chair and 10% owner
Opko Health, Inc.
CEO, Chair and 10% owner
Opko Health, Inc.
CEO, Chair and 10% owner
Opko Health, Inc.
CEO, Chair and 10% owner
Opko Health, Inc.
CEO, Chair and 10% owner
Opko Health, Inc.
CEO, Chair and 10% owner
Opko Health, Inc.
CEO, Chair and 10% owner
Opko Health, Inc.
CEO, Chair and 10% owner
Opko Health, Inc.
CEO, Chair and 10% owner
Opko Health, Inc.
CEO, Chair and 10% owner
Opko Health, Inc.
CEO, Chair and 10% owner
Opko Health, Inc.
CEO, Chair and 10% owner
Opko Health, Inc.
CEO, Chair and 10% owner
Opko Health, Inc.
CEO, Chair and 10% owner
Opko Health, Inc.
CEO, Chair and 10% owner
Opko Health, Inc.
CEO, Chair and 10% owner
Opko Health, Inc.
CEO, Chair and 10% owner
Opko Health, Inc.
CEO, Chair and 10% owner
Opko Health, Inc.
CEO, Chair and 10% owner
Opko Health, Inc.
CEO, Chair and 10% owner
About Phillip Md Et Al Frost
Phillip Frost, M.D.
Director and 10% Owner, Cocrystal Pharma, Inc. (NASDAQ: COCP)
Phillip Frost, M.D., is a seasoned physician and biotechnology executive with decades of leadership in the pharmaceutical industry. He currently serves as Chairman and Chief Executive Officer of OPKO Health, Inc. (NYSE: OPK), a position he has held since March 2007. Previously, Dr. Frost was Chairman of the Board of Teva Pharmaceuticals (NYSE: TEVA) and led IVAX Corporation as Chairman and CEO from 1987 until its acquisition by Teva in January 2006. Earlier in his career, he chaired Key Pharmaceuticals from 1972 to 1986, overseeing its growth and sale to Schering-Plough. A co-founder of Cocrystal Pharma, Inc., Dr. Frost brings extensive expertise in pharmaceutical development, commercialization, and strategic investments.
At Cocrystal Pharma, Dr. Frost serves as a Director and 10% Owner, actively participating on the Audit, Compensation, and Nominating and Corporate Governance Committees. He has demonstrated strong commitment through recent insider transactions, including the acquisition of 20,000 shares on November 25, 2025, at an average price of $0.9406 via Frost Gamma Investments Trust (for which he is trustee), and an additional 4,000 shares on November 26, 2025, totaling approximately $3,975. These bring his indirect beneficial ownership to over 1.7 million shares through the trust and 27,100 shares directly (including restricted stock units). Dr. Frost also participated in a $1.03 million private placement in October 2025, underscoring his alignment with the company's antiviral drug pipeline advancements.
Beyond corporate roles, Dr. Frost has contributed to prestigious institutions, including the Board of Regents of the Smithsonian Institution, the Board of Trustees of the University of Miami, and the Scripps Research Institutes. His board service extends to entities like Non-Invasive Monitoring Systems and Grove Bank & Trust, reflecting a broad impact in healthcare, finance, and governance.
Written by Perplexity from public sources.
Filings come from SEC EDGAR. Not investment advice.